All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Approves Afatinib for Metastatic NSCLC

July 12th 2013

The FDA has approved afatinib, along with a companion diagnostic, to treat patients with metastatic non-small cell lung cancer who express specific types of EGFR mutations.

NDA Filed for Ibrutinib in CLL and MCL

July 10th 2013

A new drug application has been submitted for ibrutinib as a therapy for previously treated CLL and MCL after positive results showed high response rates to the drug in two clinical trials.

ANA Creates Safe Patient Handling Standards

July 9th 2013

Standards established by an interprofessional workgroup.

Priority Review Granted to Neoadjuvant Breast Cancer Regimen

July 2nd 2013

The FDA has granted priority review to a regimen of pertuzumab, trastuzumab, and docetaxel for the treatment of patients with HER2-positive early-stage breast cancer.

Two Studies Show Efficacy of Ibrutinib in Hematologic Malignancies

June 24th 2013

Patients with chronic lymphocytic leukemia and mantle cell lymphoma showed high response rates to therapy with the novel targeted therapy ibrutinib, further solidifying the safety and efficacy of a drug that has proven very promising in early clinical trials.

Elotuzumab Combination Therapy Shows Promise in Previously Treated Multiple Myeloma

June 20th 2013

Patients with previously treated multiple myeloma responded well to therapy with the monoclonal antibody elotuzumab in combination with lenalidomide and low-dose dexamethasone, with a high objective response rate and longer progression-free survival.

Patient-Focused Educational Materials

June 19th 2013

Especially helpful for newly diagnosed patients.

Supreme Court Limits Ability to Patent Genes in Landmark Decision

June 13th 2013

After years of varying decisions by lower courts regarding the patents held on a test for genetic mutations associated with breast cancer, the US Supreme Court has ruled that a segment of DNA in isolation is a natural product and not eligible for patent protection.

Trebananib Significantly Improves PFS in Ovarian Cancer

June 12th 2013

Treatment with the investigational agent trebananib resulted in a significant reduction in the risk of progression or death in patients with recurrent ovarian cancer, according to a phase III study.

Emory University's Nell Hodgson Woodruff School of Nursing Joins OncLive's Strategic Alliance Partnership

June 12th 2013

OncLive is proud to announce that Emory University's Nell Hodgson Woodruff School of Nursing has joined its Strategic Alliance Partnership program.

FDA Rejects Tivozanib for Kidney Cancer, Recommends Additional Clinical Study

June 10th 2013

The FDA has rejected a new drug application for tivozanib for the treatment of advanced renal cell carcinoma, recommending an additional clinical trial to address concerns over existing clinical data.

PRO-CTCAE for Patient Reporting of Toxicities

June 10th 2013

New system hopes to improve toxicity grading accuracy.

Cancer Survivors' Day

June 6th 2013

Another year, another survivors' day.

FDA Approves Lenalidomide for the Treatment of Mantle Cell Lymphoma

June 5th 2013

The immunomodulatory agent lenalidomide is now approved by the FDA to treat patients with mantle cell lymphoma who have relapsed or whose disease has progressed after two prior therapies including at least one prior treatment with bortezomib.

Dabrafenib and Trametinib Both Approved for Advanced Melanoma

May 29th 2013

The FDA approved both dabrafenib and trametinib for the treatment of patients with metastatic or unresectable melanoma, as well as a companion diagnostic to properly identify the patients exhibiting the mutations that are targeted by these agents.

Priority Review Granted for Nab-Paclitaxel in Metastatic Pancreatic Cancer

May 23rd 2013

The FDA has granted priority review to nab-paclitaxel in combination with gemcitabine for the first-line treatment of patients with metastatic pancreatic cancer.

Pfizer Discontinues Late-Stage Trial of Inotuzumab Ozogamicin

May 21st 2013

A late-stage trial investigating inotuzumab ozogamicin as a treatment for patients with aggressive non-Hodgkin lymphoma has been halted after interim data showed the agent was unlikely to improve survival.

Four Head and Neck Cancer Highlights From ASCO 2013

May 21st 2013

This article summarizes 4 abstracts that will be discussed at the 49th Annual ASCO Meeting, focused on the treatment of patients with head and neck cancer.

New Method of Predicting Head and Neck Cancer Survival Explored

May 20th 2013

A new measure of tumor heterogeneity in patients with head and neck squamous cell carcinoma (HNSCC) was significantly associated with tumor progression and adverse treatment outcomes.

CMS Releases Data on Hospital Charges

May 20th 2013

New resource provides mechanism for viewing a hospital's billing track record.